Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study

BACKGROUND/AIMS: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical studies. The purpose of this study was to clarify the results of treatment and side effects in Ko...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Mol Hepatol
Hauptverfasser: Cho, Byeong Wook, Kim, Seok Bae, Song, Il Han, Lee, Sae Hwan, Kim, Hong Soo, Lee, Tae Hee, Kang, Young Woo, Kim, Seok Hyun, Lee, Byung Seok, Chae, Hee Bok
Format: Artigo
Sprache:Inglês
Veröffentlicht: The Korean Association for the Study of the Liver 2017
Schlagworte:
Original Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5381834/
https://ncbi.nlm.nih.gov/pubmed/28297836
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3350/cmh.2016.0053
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge